It should be emphasized that the anti-EGFR mAb cetuximab was used only as a targeting moiety while its independent pharmacological effect was not pursued in this study, as the antitumor effect of cetuximab conjugated pcpl-unloaded nanoparticles (Cet-NPs) were similar to the saline-treated control group.169 Similar results were obtained in many other experiments, indicating the great potential of EGFR mAb-decorated nanomedicines for the treatment of EGFR-overexpressing cancers.170–172. The gene discussed is EGFR; the disease is cancer.